| |
|
|
|
Taglich's Company Profile for: |
|
|
|
Most Recent Update |
Updated Research Report (Dated January 6, 2010)
|
|
What's New |
|
On March 3, 2010, Neoprobe Corporation (OTCBB: NEOP) reported results for its fourth quarter and fiscal year ended December 31, 2009.
For the quarter, the Company reported that net sales increased to $2.4 million from $2.0 million during the same period in 2008. Neoprobe reported a net loss to common of $0.4 million or $(0.00) per share for the quarter versus a net loss to common of $1.2 million or $($0.02) per share in the same period in 2008.
In comparison, Taglich Brothers’ estimates called for fourth quarter net sales of $2.6 million and a net loss to common of $1.0 million or $(0.01) per share.
For the year, the Company reported that net sales increased to $9.5 million from $7.6 million in 2008. Neoprobe reported a net loss to common of $39.8 million or $(0.54) per share in 2009 versus a net loss to common of $5.2 million or $($0.08) per share in 2008.
|
|
Company Description |
|
Neoprobe Corporation is a biomedical company that develops surgical and diagnostic products. The company primarily offers a line of gamma radiation detection equipment used in the application of sentinel lymph node biopsy, and a line of blood flow monitoring devices for various diagnostic and surgical applications. Neoprobe is also developing drugs that include Lymphoseek, which determines the spread of solid tumor cancers into the lymphatic system, and RIGScan CR, which enables surgeons to locate cancerous or disease involved tissue during colorectal cancer surgeries. |
|
Taglich Research Reports |
Updated Research Report (Dated January 6, 2010) Updated Research Report (Dated October 6, 2009) Updated Earnings Note (Dated August 13, 2009) Initial Research Report (Dated July 22, 2009)
|
All Research Reports are in Adobe Acrobat format.
(
For the latest Adobe Acrobat reader click here)
*The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. The company paid a monetary fee of $12,000 (USD) on April 2009 and will pay $12,000 (USD) on February 2010 for the creation and dissemination of research reports for the first eighteen months. After the first eighteen months of publication, the company will pay a monthly monetary fee of $2,000 (USD) to Taglich Brothers, Inc., for the creation and dissemination of research reports. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.
|
|
Send this Page to a Friend |
To send this page to a friend, just fill out the form below and press the "send it" button!
|
|
|
|
Taglich Covered Companies |
AeroCentury Corp. Anglo Swiss Resources, Inc. Baldwin Technology Company, Inc BioForce Nanosci. Holdings, Inc. Command Security Corp. CTI Industries Corp Derma Sciences, Inc. DRI Corporation Element 21 Golf Company Gulfstream International Group, Inc. Hyperdynamics Corporation INX, Inc. Leading Brands, Inc. Life Partners Holdings, Inc. Lifeway Foods, Inc. Littlefield Corporation NeoGenomics, Inc. Neoprobe Corporation Novadaq Technologies Inc. Orchids Paper Products Park City Group, Inc. Patriot Scientific Corp. Pressure BioSciences, Inc. Radiant Logistics, Inc. Simulations Plus, Inc. SMF Energy Corporation TranSwitch Corporation UFP Technologies, Inc. US 1 Industries, Inc. Williams Controls, Inc.
|
|
RSS News Feed and Alerts |
|
|
|
Disclaimers: |
|
Please Click Here
to view our Disclaimers.....
|
|
|
Home |
About Us
| Contact Us
| Disclaimers
FINRA
Public Disclosure |
SEC
Rule 11A(c) 1-6 |
Business Continuity |
Privacy Policy
|
This site is best viewed at 1024x768 with:
Internet Explorer
Click
Here for more information.
Ticker powered by TickerTech.com.
Copyright © 2000 Ticker Technologies Inc., All Rights Reserved. Quote data at least 20 minutes delayed. Please read other important disclaimer information.
|